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ABSTRACT
The Study Group for Risk Factors for Rheumatoid 
Arthritis was established by the EULAR Standing 
Committee on Investigative Rheumatology to facilitate 
research into the preclinical and earliest clinically 
apparent phases of rheumatoid arthritis (RA). This 
report describes the recommendation for terminology 
to be used to deﬁ  ne speciﬁ  c subgroups during different 
phases of disease, and deﬁ  nes the priorities for research 
in this area. Terminology was discussed by way of a 
three-stage structured process: A provisional list of 
descriptors for each of the possible phases preceding 
the diagnosis of RA were circulated to members of 
the study group for review and feedback. Anonymised 
comments from the members on this list were fed back 
to participants before a 2-day meeting. 18 participants 
met to discuss these data, agree terminologies and 
prioritise important research questions. The study group 
recommended that, in prospective studies, individuals 
without RA are described as having: genetic risk factors 
for RA; environmental risk factors for RA; systemic 
autoimmunity associated with RA; symptoms without 
clinical arthritis; unclassiﬁ  ed arthritis; which may be 
used in a combinatorial manner. It was recommended 
that the preﬁ  x ‘pre-RA with:’ could be used before 
any/any combination of the ﬁ  ve points above but only 
to describe retrospectively a phase that an individual 
had progressed through once it was known that they 
have developed RA. An approach to dating disease 
onset was recommended. In addition, important areas 
for research were proposed, including research of 
other tissues in which an adaptive immune response 
may be initiated, and the identiﬁ  cation of additional 
risk factors and biomarkers for the development of 
RA, its progression and the development of extra-
articular features. These recommendations provide 
guidance on approaches to describe phases before the 
development of RA that will facilitate communication 
between researchers and comparisons between 
studies. A number of research questions have been 
deﬁ  ned, requiring new cohorts to be established and 
new techniques to be developed to image and collect 
material from different sites. 
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Rheumatoid arthritis (RA) is a prototype immune-
mediated inﬂ  ammatory disease, characterised by 
a symmetric polyarthritis usually involving the 
small joints of the hands and feet. Other joints can 
also be involved. Rheumatoid factor (RF) and/or 
anticitrullinated protein antibody (ACPA) positive 
(‘seropositive’) RA is associated with more aggres-
sive articular disease, a higher frequency of extra-
articular manifestations and increased mortality.1 
RA is still associated with signiﬁ  cant  morbidity 
despite major developments in antirheumatic ther-
apy. Among the inﬂ  ammatory joint diseases, RA is 
the commonest and the most important in socio-
economic terms.
Over the past few years, research in the ﬁ  eld of 
RA has focused on the earliest stages of disease, 
leading to the discovery that circulating autoan-
tibodies, speciﬁ   cally immunoglobulin M-RF and 
ACPA, and increased acute phase reactants precede 
the clinical onset of the disease.2–5 These autoanti-
bodies are present a median of 5 years before clini-
cal symptoms appear.3 Subjects with arthralgia and 
these autoantibodies have an approximately 30% 
chance of developing RA within 1 year.6 These 
data form strong evidence that clinical signs and 
symptoms may be preceded by a preclinical phase 
for several years, and that the preclinical and ear-
liest clinically apparent phases of RA are likely to 
represent important therapeutic windows within 
which clinical outcomes can be dramatically modu-
lated.7 Factors such as smoking, which act during 
the preclinical phase, leading to citrullination of 
peptides and ACPA formation,8 are increasingly 
being recognised.
To facilitate research in this area, the European 
League Against Rheumatism (EULAR) Standing 
Committee on Investigative Rheumatology estab-
lished a study group in February 2011 to build a 
European network of excellence. Key aims of 
this study group were to develop a more accu-
rate understanding of the mechanisms driving 
the immunological abnormalities seen during the 
preclinical phase of RA and the stimuli that turn 
such abnormalities into a joint-centric disease, in 
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order to inform clinically relevant developments in outcome 
  prediction and therapy.
The initial remit of the study group was to agree on termi-
nologies to be used during the preclinical and earliest clinically 
apparent phases of RA and to deﬁ  ne important research ques-
tions. This report describes this process and its conclusions.
METHODS AND RESULTS
Terminology for describing phases of RA
To facilitate discussion about terminologies to be used in the 
phases of disease before individuals develop RA, a three-stage 
structured process was followed.
Stage 1
Brief summaries of widely accepted phases that individu-
als (may) pass through before the development of RA (box 1) 
were circulated to participants (19 key researchers in the ﬁ  eld; 
rheumatologists, basic scientists and a patient representative), 
who were asked to provide descriptive terms for these phases, 
and to comment on their chosen descriptive terms. Participants 
were asked to identify whether they felt that there were other 
phases that should be considered in the context of the develop-
ment of descriptive terms. Terms that are currently widely used 
to describe individuals in phases before the development of RA 
(box 2) were circulated to participants who were asked to state 
whether they felt the terms were useful and to comment further 
on them. Fifteen responses were received for stage 1.
Stage 2
Anonymised data from stage 1 were fed back to participants 
before a 2-day meeting.
Stage 3
Eighteen of the participants met during a 2-day workshop. 
Anonymised responses from previous stages were presented 
and discussed at the meeting. The following key issues were 
discussed. First, there was extensive discussion about the terms 
‘pre-RA’ and ‘preclinical RA’. It was felt that it was only appro-
priate to use these in situations in which one knew that the ﬁ  nal 
outcome was RA and when one was looking backwards through 
the patient’s history describing particular phases the patient had 
gone through. In particular, there was consensus that the term 
‘pre-RA’ suggested that the patient would deﬁ  nitely progress to 
RA; without a set of risk factors that were 100% speciﬁ  c it was 
felt that the term was inappropriate and, as highlighted by the 
patient representative, of concern to patients and their families 
if it was used as a shorthand for those individuals identiﬁ  ed at 
high risk of RA.
Second, there was consensus that the terminology used 
should be able to reﬂ  ect that the different phases: do not occur 
in all patients who eventually develop RA (eg, some patients 
may never have evidence of autoantibodies associated with RA 
during the preclinical phase of disease); do not necessarily occur 
in the same order in all patients (eg, some patients may develop 
autoantibodies before the development of inﬂ  ammatory joint 
symptoms and other patients may develop these after the devel-
opment of such symptoms).
Following these discussions a draft proposal for terminology 
was developed and this was further reﬁ  ned. The ﬁ  nal consensus 
is shown in box 3.
Recommendations for reporting of the phases of clinically 
apparent disease
Currently there is a diversity of approaches to the dating of 
‘onset’ in cohorts of patients with RA including from: the onset 
of any joint symptoms related to the current episode includ-
ing arthralgia/morning stiffness; the onset of self-reported joint 
swelling; the onset of clinically observed swelling; the time of 
fulﬁ  lment of classiﬁ  cation criteria for RA.
During the 2-day meeting, a consensus was reached that, as 
best practice, in prospective cohort studies the following dates 
are recorded:
(1) First musculoskeletal symptoms relevant (in the opinion of 
the assessing rheumatologist) to the current complaint.
(2) First persistent (ie, chronic until presentation) patient reported 
joint swelling.
(3) Initial fulﬁ  lment of criteria for RA (1987 American College 
of Rheumatology (ACR)9 and 2010 ACR EULAR)10 based on 
data obtained retrospectively from the patient’s history.
(4) Initial fulﬁ  lment of criteria for RA (1987 ACR and 2010 ACR 
EULAR) based on the rheumatologist’s assessment.
It was recognised that it may not be feasible in all situations 
to collect all these data. However, it was felt that in all situations 
investigators should report clearly what they were using as their 
‘starting point’ when reporting symptom/disease durations.
Future research agenda
During the 2-day meeting a number of areas were identiﬁ  ed as 
being in need of urgent investigation:
Identiﬁ  cation of additional risk factors and biomarkers and analysis 
of interactions between these as individuals progress through 
different phases of disease
The need to identify additional risk factors and biomarkers for 
the development of RA was unanimously agreed. Each estab-
lished and putative factor will have to be clearly deﬁ  ned, in 
order to harmonise the classiﬁ  cation of individuals between 
cohorts, for example as a precise genotype rather than an 
allelic odd ratio for a genetic factor. A clear need was identi-
ﬁ  ed for an assessment of which phases these were risk factors/
biomarkers for. For example, a particular risk factor may be 
relevant only to progression to the development of systemic 
Box 1.  Information provided to delegates for 
anonymous comment: summaries of phases that 
individuals (may) pass through before the development 
of RA. Delegates were asked to provide descriptive 
terms for these phases and to comment on their 
chosen descriptive terms.
▶    Individual at risk of RA on the basis of genetic and environ-
mental risk factors with no identiﬁ  able laboratory abnormali-
ties and no symptoms or signs of inﬂ  ammatory arthritis.
▶    Individual at risk of RA on the basis of laboratory abnormali-
ties (eg, ACPA, RF positivity) with no symptoms or signs of 
inﬂ  ammatory arthritis.
▶    Individual at risk of RA on the basis of symptoms of inﬂ  am-
matory arthritis (eg, arthralgia/morning stiffness) but no clini-
cal or imaging evidence of synovitis.
▶    Individual with synovitis on imaging but no clinically appar-
ent inﬂ  ammatory arthritis.
▶    Individual with clinically apparent inﬂ  ammatory arthritis not 
yet fulﬁ  lling classiﬁ  cation criteria for RA.
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autoimmunity associated with RA, but if assessed in patients 
in that phase would not be a risk factor for progression though 
to the development of RA. In contrast, a different risk factor 
may be relevant to progression from unclassiﬁ  ed arthritis to 
the development of RA. Using the knowledge of risk factors 
important in each phase, risk stratiﬁ  cation and prediction mod-
els might identify those individuals who would beneﬁ  t from 
intervention applicable to that phase.
Prediction of clinically relevant outcomes in addition to the 
development of RA
The heterogeneous nature of RA was acknowledged and it 
was agreed that, in addition to predicting the development of 
RA, research should look at biomarkers and risk factors for the 
rate of progression of joint destruction and the development of 
extra-articular manifestations of RA (eg, cardiovascular disease 
and pulmonary ﬁ  brosis) that could be identiﬁ  ed in individuals ‘at 
risk’ of RA. Factors related to remission would also be of inter-
est. The possible inﬂ  uence of the timing and intensity of therapy 
on these longer-term outcomes should be acknowledged.
Systemic autoimmune phase and site(s) of disease initiation
The term ‘systemic autoimmunity associated with RA’ was felt 
to be the best to describe the phase during which abnormali-
ties in various body compartments can be found preceding the 
clinical expression of the disease. Although the synovium is the 
principal site of pathology in the established phase of disease, 
it may not be the site where the disease is initiated. Systemic 
immune abnormalities in individuals without joint symptoms, 
and a lack of immune inﬁ  ltrates in the synovium during the ear-
liest phase before clinical signs and symptoms of arthritis,7 point 
to other tissues being important in the initiation of adaptive 
immune reactions. Important tissues for research include bone 
marrow, lymph nodes, the gut, periodontal tissue,11 the lung8 
and the neuroendocrine system. An initial phase, characterised 
by systemic autoimmunity without synovial inﬂ  ammation, may 
be followed by a shorter phase during which asymptomatic syn-
ovitis is present.12 13 Based on the results of research on various 
tissues during different stages of the disease, it may be possible 
to develop speciﬁ  c preventive interventions targeting the break-
ing of tolerance or the formation of autoantibodies.
Symptoms without clinical arthritis phase
It was widely recognised that many patients with RA have a 
period of symptoms likely to be related to the development of 
inﬂ  ammatory joint disease before they develop clinical arthri-
tis. Two important areas for research were identiﬁ  ed within this 
phase. First, the signiﬁ  cance of synovial and bone abnormali-
ties as assessed by imaging (eg, ultrasound or MRI), which may 
detect changes such as synovial thickening, increased synovial 
vascularity and bone marrow oedema in patients with symp-
toms without clinical arthritis, as predictors of progression to 
unclassiﬁ  ed arthritis and the development of RA. Second, the 
importance of identifying symptoms/complexes of symptoms 
that are associated with the subsequent development of RA.
DISCUSSION
The characterisation of genetic and environmental risk factors 
for RA, and the identiﬁ  cation of blood-based biomarkers predic-
tive of development of RA in as yet asymptomatic individuals, 
has led to increasing interest in the development of predictive 
and preventive strategies that can be used before the onset of 
symptoms. This comes against a background of considerable 
research looking at predictive and therapeutic approaches in 
patients with symptoms before they fulﬁ  l the classiﬁ  cation cri-
teria for RA.6 14–19 These criteria9 10 have allowed for a common 
understanding of what we mean by this phase in the patient’s 
journey. There is, however, a plethora of terms currently used 
to describe individuals in disease phases before the fulﬁ  lment 
of classiﬁ  cation criteria for RA, including ‘early RA’, ‘very early 
RA’ and ‘pre-RA’. The recommendations in this paper propose 
guidance on approaches to describe speciﬁ   c phases before 
the development of RA, which are inﬂ  uenced by our current 
thinking about aetiopathogenesis. The use of these terms in 
the manner suggested will facilitate communication between 
researchers and comparisons between studies, in much the 
same way that classiﬁ  cation criteria facilitate recruitment of 
patients with similar clinical phenotypes to clinical trials. An 
important outcome from the meeting was a decision to rec-
ommend that the use of the term ‘pre-RA’ should be limited 
to very speciﬁ  c situations. To reﬂ  ect this, the original name of 
the study group (Study Group for Preclinical and the Earliest 
Clinically Apparent Phases of Rheumatoid Arthritis) has been 
changed to Study Group for Risk Factors for Rheumatoid 
Arthritis.
Box 2.  Information provided to delegates for 
anonymous comment: commonly used terms that are 
currently used to describe individuals in phases before 
the development of RA. Delegates were asked to 
state whether they felt the terms were useful and to 
comment further on them.
▶   Pre-RA
▶   Preclinical  RA
▶   Inﬂ   ammatory  arthralgia
▶   Autoantibody-positive  arthralgia
▶   Undifferentiated  arthritis
Box 3.  Recommendation for terminology to be used 
to deﬁ  ne speciﬁ  c phases up to the development of RA
▶    In prospective studies individuals would be described as 
having:
    (a)  Genetic risk factors for RA
    (b)  Environmental risk factors for RA
    (c)  Systemic autoimmunity associated with RA
    (d)  Symptoms without clinical arthritis
   (e) Unclassiﬁ   ed  arthritis
   (f) RA
▶    The term ‘arthritis’ is used to denote clinically apparent soft 
tissue swelling or ﬂ  uid (not bony overgrowth alone). 
▶    (a) to (e) can be used in a combinatorial manner for 
example, an individual may have (a)+(b), or (a)+(b)+(c) or 
(a)+(b)+(d), etc.
▶    The preﬁ  x ‘pre-RA with:’ can be used before any/any com-
bination of (a) to (e) but only to describe retrospectively a 
phase an individual was in once it is known that they have 
developed RA.
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The terms used to describe the different phases before the 
development of RA are intentionally broad. Therefore, ‘genetic 
risk factors for RA’ and ‘environmental risk factors for RA’ delib-
erately do not deﬁ  ne any particular genetic and environmental 
risk factors. ‘Systemic autoimmunity associated with RA’ does 
not deﬁ  ne any speciﬁ  c immune abnormalities, such as any spe-
ciﬁ  c autoantibody, and ‘symptoms without clinical arthritis’ does 
not deﬁ  ne any speciﬁ  c symptoms. This was a very conscious 
decision, as restricting these categories by specifying risk factors 
and features that are currently known will render the nomencla-
ture rapidly redundant in this advancing ﬁ  eld. Future research 
will deﬁ  ne additional risk factors and features relevant to each 
of these phases, beyond current knowledge, and will assess the 
predictive utility of each of these. In addition, there are currently 
recognised biomarkers that are known to be present before the 
development of RA, which are not speciﬁ  cally reﬂ  ected in the 
nomenclature. The presence of synovitis on imaging, but not 
clinically, is an example of this. This is not to suggest that the 
study group viewed this as an unimportant biomarker. Rather, 
the nomenclature should provide a framework within which 
future research can assess at which phases, and for transit to 
which phases, this, like other biomarkers, is useful.
A number of the research questions that have been deﬁ  ned 
require new cohorts, of asymptomatic individuals and of 
patients, to be established and new techniques to be developed 
to image and collect material from different sites. The identi-
ﬁ  cation of uniform core datasets that can be collected in stan-
dardised ways across cohorts is an important goal. Furthermore, 
standard operating procedures for the collection, handling and 
storage of samples, such as serum and RNA, should be agreed 
to ensure good and consistent quality of the biomaterial. Given 
the inherent conﬂ  ict between the desire to collect material in 
a uniform and optimal manner and the constraints of working 
in a clinical environment where such collection is not always 
feasible, the description of how each sample was collected, 
handled and stored, will be very important.
As knowledge evolves it is important not to leave its true 
target audience behind. Individuals without RA need to be 
informed of the rationale for and value of predicting risk and 
intervening and the need to have a clear understanding of the 
risks and beneﬁ  ts of such approaches. Clarity of terminology 
and the involvement of users through all phases of the research 
process will help achieve this.
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